$HLXB News
Last published 8mo ago
- 8mo agoBBOTHLXBBBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressGlobeNewswireBBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy
- 12mo agoBBOTHLXBBBOT Reports Third Quarter 2025 Financial Results and Update on Corporate ProgressGlobeNewswireBBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced
- 1y agoBBOTHLXBBBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K InhibitionGlobeNewswireBusiness combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million
- 1y agoBBIOHLXBHelix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology TherapeuticsGlobeNewswireGross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate for a biotech de-SPAC
- 1y agoBBIOHLXBHelix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business CombinationGlobeNewswireExtraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special
- 1y agoBBIOHLXBBridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting MedicinesBusiness WireTotal proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading
- 2y agoHLXBHelix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional SharesBusiness WireHelix Acquisition Corp. II (NASDAQ:HLXB) (the "Company") announced today that on February 13, 2024 it closed the initial public offering of 18,400,000 Class A ordinary shares which includes 2,400,000 shares issued
- 2y agoHLXBHelix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public OfferingBusiness WireHelix Acquisition Corp. II (the "Company") announced today that it priced its upsized initial public offering of 16,000,000 Class A ordinary shares at $10.00 per share. The shares will be listed on The Nasdaq Global